INVEX Therapeutics Ltd (IXC) - Total Liabilities
Based on the latest financial reports, INVEX Therapeutics Ltd (IXC) has total liabilities worth AU$176.49K AUD (≈ $124.88K USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
INVEX Therapeutics Ltd - Total Liabilities Trend (2019–2025)
This chart illustrates how INVEX Therapeutics Ltd's total liabilities have evolved over time, based on quarterly financial data. See working capital to net assets of INVEX Therapeutics Ltd to evaluate short-term liquidity relative to the company's equity base.
INVEX Therapeutics Ltd Competitors by Total Liabilities
The table below lists competitors of INVEX Therapeutics Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
HYPERCHARGE NETWORKS CORP
F:PB7
|
Germany | €3.87 Million |
|
NB Private Equity Partners Ltd
LSE:NBPE
|
UK | GBX96.67 Million |
|
Cohort
LSE:CHRT
|
UK | GBX247.03 Million |
|
Future Consumer Limited
NSE:FCONSUMER
|
India | Rs8.53 Billion |
|
Careteq Ltd
AU:CTQ
|
Australia | AU$3.20 Million |
|
Enthusiast Gaming Holdings Inc
TO:EGLX
|
Canada | CA$63.28 Million |
|
Upsellon Brands Holdings Ltd
TA:UPSL
|
Israel | ILA1.70 Million |
Liability Composition Analysis (2019–2025)
This chart breaks down INVEX Therapeutics Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see IXC stock market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 26.76 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.04 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.04 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how INVEX Therapeutics Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for INVEX Therapeutics Ltd (2019–2025)
The table below shows the annual total liabilities of INVEX Therapeutics Ltd from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | AU$220.59K ≈ $156.08K |
-48.89% |
| 2024-06-30 | AU$431.63K ≈ $305.41K |
-72.55% |
| 2023-06-30 | AU$1.57 Million ≈ $1.11 Million |
+56.58% |
| 2022-06-30 | AU$1.00 Million ≈ $710.55K |
+52.47% |
| 2021-06-30 | AU$658.61K ≈ $466.01K |
-67.32% |
| 2020-06-30 | AU$2.02 Million ≈ $1.43 Million |
+115.43% |
| 2019-06-30 | AU$935.49K ≈ $661.92K |
-- |
About INVEX Therapeutics Ltd
Invex Therapeutics Ltd, a biopharmaceutical company, engages in the research and development of treatments for neurological conditions in Australia. It is involved in developing Exenatide, a treatment for neurological conditions derived from or involving raised intracranial pressure, such as idiopathic intracranial hypertension, acute stroke, and traumatic brain injury that has completed Phase II… Read more